Indian Journal of Pharmaceutical Chemistry and Analytical Techniques (IJPCAT)
ISSN: 3049-3765 | Vol. 02, Issue-01, Jan-Feb, 2026, pp. 45-66
https://ijpcat.com/1

Quantum Dots in Materia Medica: Emerging Tools for Bioimaging and Targeted Drug Delivery

Nidhi Katendra[1], Suman Chandel[2], Deleshwar Kumar[3], Vinay Sagar Verma[3], Neha Mandle[4*]

[1]Rungta Institute of Pharmaceutical Sciences, Kohka, Bhilai, C.G. 490023.
[2]Maitri College of Pharmacy, Anjora, Durg, C.G. 491001.
[3]Kamla Institute of Pharmaceutical Sciences, Junwani, Bhilai, C.G. 490020.
[4]Shri Shankaracharya College of Pharmaceutical Sciences, Junwani, Bhilai, C.G. 490020.

***Corresponding Author E-mail: nehamandle1996@gmail.com**

Abstract:

Quantum dots (QDs) have revolutionized biomedical sciences by offering exceptional optical, electronic, and chemical versatility for simultaneous imaging, diagnostics, and targeted drug delivery. These semiconductor nanocrystals (2–10 nm), with their size-dependent fluorescence, high quantum yield, and superior photostability compared to conventional organic dyes, enable multiplexed bioimaging, real-time drug tracking, and precisely controlled theranostic applications. The tunable surface chemistry of QDs allows functional modification with targeting ligands, therapeutic agents, and biocompatible coatings, facilitating receptor-mediated targeting and stimuli-responsive drug release across diverse disease contexts. Advanced synthesis strategies—including colloidal, hydrothermal, and green (biogenic) methods—have enabled the production of eco-friendly alternatives to heavy-metal-based QDs, such as carbon quantum dots, graphene QDs, and silicon-based systems, which maintain superior optical performance while minimizing cytotoxicity concerns. Functionally, QDs act as multifunctional nanocarriers via mechanisms including fluorescence resonance energy transfer (FRET), pH-responsive release, enzyme-triggered activation, and light-mediated delivery. Pharmacokinetically, QD biodistribution is governed by size, surface charge, and coating, with optimal formulations achieving prolonged circulation and tissue-specific accumulation. Clinical successes in tumor imaging, gene delivery tracking, and theranostic platforms underscore their translational potential. However, challenges including long-term toxicity from heavy metals, physicochemical stability in biological fluids, batch-to-batch reproducibility, and regulatory standardization remain critical barriers. The integration of artificial intelligence for imaging interpretation and predictive pharmacokinetic modeling, alongside advances in biodegradable and personalized QD engineering, represents the next frontier. Collectively, quantum dots epitomize the convergence of materials science, molecular pharmacology, and digital health—transforming precision diagnostics and therapy into seamlessly integrated, patient-centric nanomedicines.

Keywords: Quantum Dots, Nanomedicine, Targeted Drug Delivery, Bioimaging, Theranostics, Fluorescence, Nanocarriers, Photodynamic Therapy, Carbon Quantum Dots, Biodistribution, Pharmacokinetics, Precision Medicine, Stimuli-Responsive Delivery, Metal-Free Nanoparticles

Received: Nov. 19, 2025 **Revised:** Dec. 30, 2025 **Accepted:** Jan. 29, 2026 **Published:** Feb 25, 2026

DOI: https://doi.org/10.64062/IJPCAT.Vol2.Issue1.5

https://ijpcat.com/index.php/1/issue/archive

1. Introduction

Nanotechnology has revolutionized the landscape of modern pharmacology by enabling precise control over drug delivery, bioimaging, and diagnostic applications at the molecular and cellular levels. The convergence of nanoscience with biomedical engineering has led to the creation of nanoscale systems capable of interacting with biological components such as proteins, nucleic acids, and cellular membranes in a highly specific and controlled manner. Among these, quantum dots (QDs) have emerged as one of the most promising and versatile nanomaterials due to their unique optical and electronic characteristics that distinguish them from conventional organic dyes or fluorescent proteins. These semiconductor nanocrystals, typically ranging from 2 to 10 nanometers in diameter, exhibit remarkable size-dependent fluorescence, high photostability, and broad excitation with narrow emission spectra, making them ideal candidates for a variety of biomedical applications [1-2].

The emergence of quantum dots as multifunctional nanosystems in pharmacology represents a major breakthrough in the field of bioimaging and targeted drug delivery. Unlike traditional nanoparticles that primarily serve as passive carriers, QDs can simultaneously perform diagnostic and therapeutic roles, leading to the concept of "theranostics"—a combination of therapy and diagnostics within a single platform. By adjusting the size, shape, and composition of quantum dots, researchers can precisely tune their emission properties across the visible to near-infrared (NIR) spectrum, allowing for deep-tissue imaging and real-time monitoring of drug biodistribution. Their high quantum yield and resistance to photobleaching offer a significant advantage in long-term imaging of biological systems, where conventional fluorophores rapidly degrade [3].

The physicochemical properties of quantum dots are determined by their core–shell architecture and surface functionalization. The core, composed of semiconducting materials such as CdSe, CdTe, or InP, governs the electronic properties, while the shell, often made of ZnS or other inert materials, enhances photostability and reduces surface defects. Surface coating and conjugation with biocompatible molecules—such as polyethylene glycol (PEG), peptides, antibodies, or aptamers—enable quantum dots to circulate stably in biological fluids, evade immune detection, and specifically target diseased cells or tissues. This tunability in structure and chemistry underpins their growing use in drug delivery, biosensing, diagnostics, and molecular imaging [4].

In drug delivery, quantum dots serve as intelligent carriers capable of transporting therapeutic agents directly to target sites. Their large surface area allows for high drug loading capacity, while surface modification ensures site-specific recognition, minimizing off-target effects. Moreover, QDs can be engineered to respond to environmental triggers such as pH, temperature, or enzymatic activity, enabling controlled and stimuli-responsive drug release. In biosensing, quantum dots provide exceptional sensitivity in detecting biological analytes, including proteins, nucleic acids, and small molecules, due to their strong and tunable fluorescence signals. They have been successfully integrated into fluorescence resonance energy transfer (FRET) systems and microarrays, advancing rapid diagnostics and biomolecular interaction studies. Meanwhile, in bioimaging, quantum dots enable multiplexed imaging—simultaneous visualization of multiple targets—due to their narrow emission

bandwidths and broad excitation range, which are unachievable with traditional fluorophores [5-6].

However, despite their enormous potential, the use of quantum dots in pharmacology is not without challenges. The toxicity associated with heavy-metal-based QDs, particularly those containing cadmium or tellurium, raises safety concerns for in vivo applications. Recent advances have focused on developing biocompatible and heavy-metal-free alternatives, such as carbon quantum dots, graphene quantum dots, and silicon-based QDs, which maintain desirable optical characteristics while minimizing cytotoxicity. Surface passivation and encapsulation strategies have also been employed to mitigate potential leaching of toxic ions and improve biocompatibility. These innovations have paved the way for the translation of QD-based systems from laboratory research to preclinical and clinical settings [7-8].

The rapid evolution of QD technology signifies a paradigm shift in precision medicine, where imaging, diagnosis, and targeted therapy can be seamlessly integrated. The interdisciplinary nature of this field—bridging materials science, chemistry, biology, and pharmacology—has led to continuous progress in designing QDs with improved optical efficiency, biostability, and pharmacokinetic profiles. Their ability to provide real-time insights into drug distribution and therapeutic response makes them invaluable for understanding disease mechanisms and optimizing treatment regimens.

This review aims to provide a comprehensive overview of the role of quantum dots in pharmacology, emphasizing their design, functionalization, and application in bioimaging and targeted drug delivery. It explores the fundamental principles governing their unique optical behavior, fabrication strategies that ensure biocompatibility, and the mechanisms by which they interact with biological systems. Additionally, the review discusses pharmacokinetic and toxicity considerations essential for clinical translation and highlights emerging trends such as metal-free quantum dots, hybrid nanocomposites, and AI-integrated QD imaging systems. By synthesizing recent advancements and ongoing challenges, this work seeks to underscore the transformative potential of QDs in shaping the future of nanomedicine and personalized therapeutics [9-10].Figure 1



Figure 1: Schematic representation of a quantum dot structure depicting the core–shell configuration, surface functionalization, and emission tuning for bioimaging and drug delivery applications.

2. Fundamentals of Quantum Dots

Quantum dots (QDs) are nanoscale semiconductor particles typically ranging from 2 to 10 nanometers in diameter, exhibiting unique size-dependent optical and electronic properties due to the quantum confinement effect. This phenomenon occurs when the size of the particle becomes comparable to or smaller than the exciton Bohr radius, leading to discrete energy levels. As a result, QDs display tunable fluorescence emission, where smaller dots emit light toward the blue end of the spectrum and larger dots toward the red end. This property makes them highly suitable for biomedical imaging, diagnostics, and therapeutic applications, offering advantages such as enhanced brightness, photostability, and resistance to photobleaching compared to traditional organic dyes.

Quantum dots can be broadly classified into several categories based on their chemical composition and core structure. The most common are semiconductor QDs, including cadmium selenide (CdSe), cadmium telluride (CdTe), and indium phosphide (InP), which exhibit sharp emission spectra and strong luminescence. However, due to toxicity concerns from heavy metals like cadmium, alternative carbon-based QDs and graphene quantum dots (GQDs) have gained attention for their superior biocompatibility, ease of surface functionalization, and environmental safety. In recent years, perovskite quantum dots (PQDs)—notably those based on cesium lead halides ($CsPbX_3$)—have emerged for their exceptional quantum yields and narrow emission profiles, although their stability and toxicity remain challenges for biomedical use [11-12].

Structurally, most QDs consist of a core–shell architecture, where the core defines the fundamental optical properties, and the shell, typically made of a wider bandgap material like ZnS, passivates surface defects and enhances luminescence efficiency. The surface ligands attached to the QD surface play a vital role in determining solubility, biocompatibility, and functionalization capacity. By engineering the surface chemistry with biocompatible molecules such as polyethylene glycol (PEG), peptides, or antibodies, QDs can be made water-dispersible and targeted to specific biomolecules or tissues, enabling their application in bioimaging, biosensing, and drug delivery systems.

However, despite their remarkable photophysical characteristics, toxicological concerns remain a key limitation, particularly for QDs composed of cadmium or lead. Upon degradation or prolonged exposure, heavy metal ions can leach out, leading to oxidative stress, cytotoxicity, and potential genotoxic effects. To mitigate these risks, research has shifted toward developing eco-friendly and non-toxic QDs, such as carbon dots (C-dots) and silicon-based QDs, which retain strong luminescence while ensuring biological safety [13-14].

In essence, understanding the fundamentals of quantum dots—their structure, optical behavior, and toxicity—is essential for their rational design and biomedical application. This foundation enables the tailoring of QDs for specific pharmacological purposes, such as targeted drug delivery, real-time bioimaging, and theranostic systems.

Table 1: Classification of quantum dots based on composition, size, emission wavelength, and biomedical relevance.

Type of Quantum Dot	Composition	Size Range (nm)	Emission Wavelength (nm)	Biomedical Features	Toxicity Concern	Reference
CdSe/CdTe QDs	CdSe, CdTe	2–10	450–650	High brightness, tunable emission	High (Cd-based)	15
InP QDs	InP/ZnS	3–8	520–630	Low toxicity, good photostability	Moderate	16
Carbon QDs	Carbon-based amorphous core	1–8	400–550	Excellent biocompatibility, low cost	Negligible	17
Graphene QDs (GQDs)	Graphene fragments	2–10	450–600	High surface area, strong fluorescence	Low	18
Perovskite QDs (PQDs)	$CsPbX_3$ (X = Cl, Br, I)	4–12	420–720	High quantum yield, narrow FWHM	Moderate to high (Pb-based)	19

This table provides an overview of the major classes of QDs, their optical characteristics, and their relevance in pharmacology, highlighting the ongoing shift from heavy-metal-based systems toward biocompatible alternatives.

3. Synthesis and Surface Functionalization

The synthesis of quantum dots (QDs) is a critical step that determines their physicochemical characteristics, optical properties, and suitability for biomedical applications. Broadly, QD synthesis strategies are classified into top-down and bottom-up approaches, each offering distinct advantages and limitations.

In top-down synthesis, bulk materials are physically or chemically broken down into nanosized particles. Techniques such as laser ablation, electrochemical etching, and mechanical milling are commonly employed. While these methods offer simplicity and scalability, they often result in poor size uniformity, surface defects, and limited control over optical properties, making them less favorable for biomedical use.

Conversely, bottom-up synthesis involves the assembly of quantum dots from atomic or molecular precursors, allowing for precise control over particle size, shape, and composition. This approach typically yields high-quality QDs with excellent crystallinity and tunable emission characteristics. Common bottom-up methods include colloidal synthesis, hydrothermal and solvothermal methods, and microwave-assisted synthesis.

- Colloidal synthesis is the most widely used chemical route, involving the reaction of metal precursors and stabilizing ligands in organic solvents at elevated temperatures. It provides excellent control over QD size distribution and photophysical properties, especially for semiconductor QDs like CdSe or InP.

- Hydrothermal and solvothermal synthesis methods utilize high-pressure and high-temperature conditions in water or organic solvents, respectively. These approaches enable the growth of QDs with good crystallinity and improved biocompatibility, making them suitable for aqueous and biological environments.
- Microwave-assisted synthesis has emerged as a rapid, energy-efficient, and scalable technique, offering uniform heating, reduced reaction times, and narrow size distribution of the resulting QDs.

In recent years, the demand for eco-friendly and non-toxic QD synthesis has led to the exploration of biogenic or green synthesis methods. These approaches employ plant extracts, microorganisms, and biomolecules (such as proteins, polysaccharides, or amino acids) as reducing and capping agents. For instance, carbon and graphene QDs synthesized using tea polyphenols, lemon peel extracts, or algae biomass exhibit excellent fluorescence, water dispersibility, and low cytotoxicity. This sustainable approach not only eliminates hazardous chemicals but also enhances the biocompatibility of the QDs, making them ideal for pharmacological and diagnostic applications [21-22].

Once synthesized, surface functionalization becomes essential to tailor QDs for biomedical use. Pristine QDs often possess hydrophobic surfaces, requiring surface modification to improve solubility and compatibility with biological systems. Functionalization strategies involve coating or conjugating the QD surface with hydrophilic polymers, proteins, antibodies, or targeting ligands to enhance stability, specificity, and pharmacokinetic behavior.

- Polyethylene glycol (PEG) is the most commonly used polymer for surface modification. PEGylation improves circulation time, minimizes immune recognition, and reduces opsonization by serum proteins.
- Protein and antibody conjugation enables targeted delivery, allowing QDs to recognize and bind specific cellular receptors or tumor markers.
- Ligand functionalization, using molecules like folic acid, transferrin, or peptides, provides receptor-mediated targeting, improving therapeutic index and reducing off-target effects.

The surface chemistry of QDs directly influences their biocompatibility, biodistribution, and clearance. Hydrophilic coatings increase solubility and reduce aggregation in physiological conditions, while surface charge and functional group composition determine cellular uptake and interaction with biomolecules. A well-engineered surface can thus transform QDs from simple imaging agents into multifunctional nanoplatforms for drug delivery, diagnostics, and theranostics.

In summary, the synthesis and surface functionalization of quantum dots represent the cornerstone of their pharmacological utility. The convergence of controlled synthesis, green chemistry, and bioconjugation techniques is paving the way for safer, more efficient, and clinically translatable QD-based drug delivery systems [23-24].

Table 2: Overview of quantum dot synthesis methods, key parameters, and their implications for biomedical applications.

Synthesis Method	Approach Type	Precursors/Agents Used	Advantages	Limitations	Biomedical Suitability	Reference
Laser Ablation	Top-down	Bulk semiconductor target	Simple, scalable	Poor size control, surface defects	Limited	25
Colloidal Synthesis	Bottom-up	Metal salts, surfactants, ligands	Excellent control over size & shape	Requires toxic solvents	High	26
Hydrothermal/Solvothermal	Bottom-up	Metal precursors in water/solvent	Good crystallinity, aqueous compatibility	Long reaction time	High	27
Microwave-Assisted	Bottom-up	Organic/inorganic precursors	Rapid, uniform heating, energy-efficient	Requires optimization	Very high	28
Biogenic (Green) Synthesis	Bottom-up	Plant extracts, biomolecules	Eco-friendly, biocompatible	Limited quantum yield	Excellent	29

This synthesis-functionalization framework provides the foundation for developing next-generation quantum dots optimized for safety, stability, and targeted pharmacological applications.

4. Mechanisms of Bioimaging and Signal Detection

Quantum dots (QDs) have emerged as transformative tools in bioimaging and molecular diagnostics, primarily due to their exceptional optical characteristics, tunable fluorescence, and high resistance to photobleaching. Unlike traditional organic dyes and fluorescent proteins, QDs exhibit size-dependent emission, broad absorption spectra, and narrow, symmetric emission peaks, making them ideal for multiplexed imaging and long-term cellular tracking in pharmacological and biomedical studies [30].

At the core of QD-based imaging lies fluorescence resonance energy transfer (FRET), a phenomenon where energy is transferred non-radiatively from an excited donor fluorophore (such as a QD) to an acceptor molecule within close proximity (typically 1–10 nm). In FRET-based biosensing, QDs act as efficient energy donors due to their broad absorption cross-section and high quantum yield, enabling real-time monitoring of protein–protein interactions, gene expression, and enzymatic activity. The strong and stable fluorescence output from QDs enhances signal sensitivity and reduces photobleaching, providing longer observation windows compared to conventional fluorophores.

Quantum yield enhancement is another crucial aspect that determines imaging performance. The emission intensity and brightness of QDs can be tuned by modifying their core–shell structure (e.g., CdSe/ZnS, InP/ZnS) and surface passivation layers. A thicker shell improves quantum confinement and reduces surface defects, resulting in stronger fluorescence and prolonged emission lifetimes. These properties enable QDs to serve as robust probes in fluorescence microscopy, in vivo imaging, and biosensing applications, even under challenging physiological conditions [31-32].

In advanced imaging modalities, QDs have shown remarkable potential in photoluminescence, two-photon excitation, and near-infrared (NIR) bioimaging.

- Photoluminescence imaging utilizes the intrinsic light emission of QDs upon excitation, allowing detection of biomolecules with high sensitivity and spatial resolution.
- Two-photon imaging, using NIR lasers, enables deep-tissue visualization with minimal photodamage and autofluorescence, ideal for brain and tumor imaging.
- NIR-emitting QDs (e.g., CdTe, InAs, PbS, and carbon QDs) are particularly valuable for in vivo imaging due to enhanced tissue penetration and reduced background interference, allowing for clearer, deeper, and more precise biological imaging.

Functionalizing QDs with biomolecules—such as antibodies, peptides, aptamers, or nucleic acids—further broadens their utility in real-time cellular imaging. These QD–biomolecule conjugates can selectively bind to cellular receptors or intracellular targets, enabling specific labeling of organelles, tumor markers, or signaling pathways. For instance, QDs conjugated with anti-HER2 antibodies have been successfully used to visualize breast cancer cells, while QD–DNA hybrids facilitate the tracking of gene expression dynamics in live cells.

Compared to organic dyes and traditional imaging agents, QDs offer several clear advantages:

- Superior brightness and photostability, enabling long-term imaging without significant signal decay.
- Broad excitation and narrow emission spectra, allowing simultaneous detection of multiple biomarkers (multiplexing).
- Resistance to photobleaching, ensuring consistent fluorescence intensity over extended observation periods.
- Tunable emission wavelengths, achieved simply by controlling QD size or composition.

These features make QDs ideal for diverse biomedical applications, including tumor imaging, gene delivery tracking, and live-cell visualization. In tumor imaging, QDs conjugated with tumor-specific ligands can localize precisely to malignant tissues, enabling early detection and image-guided surgery. In gene tracking, QDs bound to nucleic acids allow researchers to follow intracellular transport and expression kinetics with high spatiotemporal resolution. For live-cell imaging, their non-fading luminescence provides real-time insights into dynamic cellular events such as endocytosis, signal transduction, and apoptosis [33-34].

Overall, quantum dots represent a significant leap forward in pharmacological imaging, bridging the gap between molecular biology and nanotechnology. Their ability to deliver brighter, longer, and more multiplexed signals than conventional dyes paves the way for next-generation diagnostic and therapeutic platforms, combining visualization and drug delivery within a single nanostructure.

Table 3: Comparison of QDs and conventional fluorophores for biomedical imaging.

Parameter	Quantum Dots (QDs)	Conventional Fluorophores (Organic Dyes, Proteins)	Reference
Emission Tunability	Size-dependent (400–1000 nm)	Fixed emission wavelength	35
3Brightness	Very high (10–20× brighter)	Moderate	36
Photostability	Excellent, minimal photobleaching	Poor to moderate	37
Excitation Spectrum	Broad	Narrow	38
Emission Spectrum	Narrow, symmetric	Broad, asymmetric	39
Multiplexing Capability	High (multiple colors with one excitation source)	Limited	40
Biocompatibility	Moderate (depends on surface modification)	High	41
Tissue Penetration (NIR)	Excellent (up to several mm)	Limited	42
Lifetime & Signal Duration	Long (nanoseconds to microseconds)	Short	43
Applications	Tumor imaging, live-cell tracking, FRET biosensing, deep-tissue visualization	Immunofluorescence, simple labeling, short-term imaging	44

This comprehensive understanding of QD-based imaging mechanisms underscores their expanding role in **precision pharmacology**, enabling real-time molecular visualization and paving the way for theranostic nanomedicine.

5. Quantum Dots in Targeted Drug Delivery

Quantum dots (QDs) have evolved far beyond their original role as fluorescent imaging agents, emerging as dual-function nanoplatforms that integrate diagnostic and therapeutic capabilities, a concept known as theranostics. Their tunable optical properties, high surface-to-volume ratio, and versatile surface chemistry make them ideal candidates for targeted drug delivery systems capable of both visualizing and treating disease at the molecular level. By simultaneously delivering therapeutic payloads and providing real-time imaging feedback, QD-based formulations represent a significant leap toward personalized and precision medicine [45].

The dual role of QDs in pharmacology stems from their ability to act as diagnostic probes while serving as drug carriers. The semiconductor core (e.g., CdSe, CdTe, or InP) is typically coated with a biocompatible shell such as ZnS or polymeric layers, providing functional sites for drug conjugation. This allows drugs, peptides, antibodies, or small interfering RNAs (siRNAs) to be covalently attached or adsorbed onto the QD surface. The result is a multifunctional nanoconjugate capable of targeting specific cells, monitoring intracellular localization, and releasing therapeutic agents in response to biological stimuli.

Conjugation strategies vary depending on the therapeutic application and desired release profile. Covalent coupling via carboxyl, amine, or thiol groups enables stable attachment of drugs like doxorubicin, paclitaxel, or curcumin, while electrostatic interactions and hydrophobic encapsulation are used for reversible or controlled binding. Furthermore, QDs functionalized with biomolecular ligands—such as folic acid, transferrin, aptamers, or monoclonal antibodies—facilitate receptor-mediated targeting, ensuring selective accumulation in diseased tissues while minimizing off-target effects. For instance, folate-receptor-targeted CdSe/ZnS QDs have demonstrated enhanced delivery of doxorubicin to tumor cells, significantly improving cytotoxic efficacy and imaging contrast [46-47].

The mechanisms of cellular uptake for QD-based nanocarriers primarily involve endocytosis, where the particles are internalized through clathrin- or caveolin-mediated pathways. Once internalized, QDs localize within endosomes or lysosomes, from which drugs can be released in a stimuli-responsive manner. These stimuli can include pH, light irradiation, or enzyme activity, each offering a distinct advantage for spatial and temporal control of drug release.

- pH-sensitive systems exploit the acidic microenvironment of tumors or intracellular vesicles, triggering drug detachment under low pH conditions. For example, doxorubicin–QD conjugates have been engineered to release their drug cargo selectively in acidic tumor environments.
- Light-responsive systems, particularly those using near-infrared (NIR) irradiation, allow for externally controlled release with high spatial precision, minimizing systemic toxicity.
- Enzyme-responsive QD carriers incorporate peptide linkers that are cleaved by disease-specific enzymes (e.g., matrix metalloproteinases in cancer or proteases in infections), ensuring drug activation only in pathological sites.

The theranostic capability of QDs also enables real-time tracking of drug distribution and release kinetics. Fluorescent imaging allows visualization of cellular uptake, intracellular trafficking, and therapeutic response, offering valuable pharmacokinetic insights. This integration of therapy and diagnostics in a single nanosystem not only improves treatment efficiency but also enhances safety and monitoring accuracy.

Examples of QD-based nanoconjugates demonstrate their broad therapeutic potential across multiple disease domains:

- Cancer Therapy: CdSe/ZnS QDs conjugated with doxorubicin, paclitaxel, or siRNA have shown superior tumor targeting and reduced systemic toxicity. In multifunctional systems, QDs also act as photothermal or photodynamic agents, generating reactive oxygen species (ROS) or heat under laser excitation to induce localized tumor destruction.
- Neurological Disorders: QDs functionalized with transferrin or peptides like TAT can cross the blood–brain barrier (BBB), enabling delivery of neuroprotective agents and gene silencing molecules for treating diseases such as Alzheimer's or glioblastoma.
- Infectious Diseases: QD–antibiotic conjugates, such as ciprofloxacin-modified QDs, have been developed to target bacterial membranes while simultaneously imaging infection sites, enabling early diagnosis and treatment monitoring.

The integration of targeting ligands, stimuli-responsive release mechanisms, and imaging functionality makes QD-based systems a cornerstone of next-generation nanomedicine. However, their translation to clinical practice still faces challenges related to toxicity,

biodegradation, and long-term accumulation—issues currently being addressed through the use of carbon, graphene, and perovskite QDs, which offer improved biocompatibility and reduced heavy metal content [48-49].

In summary, QDs are redefining targeted drug delivery by merging diagnostic precision with therapeutic efficacy. Their adaptability allows researchers to design systems tailored to specific diseases, therapeutic molecules, and physiological barriers, positioning QD-based theranostics as one of the most promising frontiers in pharmacological innovation.

6. Pharmacokinetics, Biodistribution, and Toxicity

Quantum dots (QDs) have revolutionized pharmacology and nanomedicine by offering exceptional optical and electronic properties, but their transition from bench to bedside largely depends on understanding their pharmacokinetics, biodistribution, and toxicity. These parameters are crucial for determining their safety, therapeutic efficiency, and clinical applicability. While QDs have shown immense potential in bioimaging, targeted drug delivery, and theranostics, their complex physicochemical properties—such as size, charge, surface chemistry, and composition—significantly influence their in vivo behavior. A detailed understanding of how QDs are distributed, metabolized, and excreted within biological systems is essential to minimize toxicity and ensure biocompatibility.

The pharmacokinetic behavior of quantum dots is governed by several intrinsic and extrinsic factors, primarily their size, surface charge, coating, and administered dose. Size plays a pivotal role in determining the circulation half-life and tissue penetration of QDs. Generally, nanoparticles smaller than 5 nm are rapidly cleared via renal excretion, whereas larger particles (>20 nm) are more likely to accumulate in the liver and spleen due to uptake by the reticuloendothelial system (RES). Intermediate-sized QDs (around 10–15 nm) can achieve a balance between prolonged circulation and effective tissue penetration, making them suitable for targeted delivery applications [50-51].

Surface charge also influences QD biodistribution. Positively charged QDs exhibit stronger interactions with negatively charged cell membranes, enhancing cellular uptake but also potentially increasing cytotoxicity. Conversely, negatively charged or neutral QDs tend to exhibit reduced nonspecific binding and longer circulation times. This interplay between charge and biointeraction determines not only their pharmacokinetics but also their immune compatibility.

Surface coating or functionalization is another decisive factor. Coatings such as polyethylene glycol (PEG), phospholipids, and zwitterionic polymers improve the hydrophilicity and stability of QDs in biological environments. PEGylation, in particular, reduces opsonization by serum proteins, thereby evading phagocytosis and extending circulation time. Furthermore, ligand-based surface modification—such as folic acid, antibodies, or peptides—facilitates receptor-mediated targeting to specific cells or tissues, enhancing therapeutic specificity and reducing off-target accumulation.

Lastly, dose determines the overall pharmacodynamic and toxicological impact. At lower doses, QDs can circulate without triggering significant immune or inflammatory responses, whereas at higher concentrations, aggregation and organ accumulation may lead to oxidative stress, inflammation, and cytotoxicity. Therefore, an optimal balance between effective therapeutic concentration and systemic safety must be maintained [52].

After administration, QDs distribute throughout the body based on their physicochemical properties and the route of administration. Intravenous injection remains the most common route for experimental studies, leading to immediate systemic circulation. QDs primarily accumulate in organs rich in macrophages—such as the liver, spleen, and lymph nodes—due to phagocytosis by Kupffer cells and splenic macrophages. Smaller QDs may pass through glomerular filtration in the kidneys, leading to renal clearance, while larger or more hydrophobic QDs are typically sequestered in the hepatobiliary system.

The renal clearance pathway is favorable for minimizing long-term retention and toxicity. For renal excretion to occur, QDs must generally have a hydrodynamic diameter below 6 nm. QDs coated with hydrophilic ligands or zwitterionic surfaces often exhibit enhanced renal clearance, reducing the risk of organ accumulation. On the other hand, the hepatobiliary clearance pathway dominates for larger or lipophilic QDs, where they are metabolized by hepatocytes and excreted via bile into the gastrointestinal tract. However, this route is slower and may lead to prolonged retention, posing potential toxicity risks [53-54].

The biodistribution of QDs can also be tissue-specific depending on their functionalization. For instance, transferrin-conjugated QDs target the brain via transferrin receptors on the blood-brain barrier, while folate- or RGD-peptide-conjugated QDs accumulate preferentially in tumor tissues due to enhanced receptor-mediated uptake. Importantly, QDs with prolonged circulation may benefit imaging and drug delivery, but extended residence in organs like the liver and spleen necessitates strategies to mitigate potential toxicity.

The toxicological concerns associated with quantum dots largely stem from their core composition. Traditional QDs, such as CdSe, CdTe, or CdS, contain cadmium—a heavy metal known for its potential cytotoxicity, genotoxicity, and carcinogenicity. Under physiological conditions, QDs may undergo photooxidation or surface degradation, releasing Cd^{2+} ions, which can disrupt mitochondrial function, generate reactive oxygen species (ROS), and induce apoptosis or necrosis in exposed cells.

Cd-based QDs have shown high quantum yield and brightness, but their long-term safety in vivo remains questionable. Studies have demonstrated dose-dependent toxicity, with accumulation in the liver and spleen leading to inflammatory responses and oxidative damage. The degradation of QD surfaces under UV exposure or oxidative stress exacerbates these effects.

To overcome these limitations, Cd-free QDs such as InP/ZnS, $CuInS_2$, ZnSe, and carbon dots (CDs) have been developed. These alternatives maintain excellent photoluminescent properties while significantly reducing metal ion toxicity. Carbon dots and graphene quantum dots, in particular, exhibit superior biocompatibility, negligible cytotoxicity, and easy functionalization, making them ideal candidates for clinical translation. Although Cd-free QDs generally exhibit lower quantum yields than their cadmium-based counterparts, continuous advancements in surface passivation and core–shell engineering have closed much of this performance gap.

Several engineering strategies have been adopted to minimize the inherent toxicity of QDs while maintaining their functional properties. Encapsulation within biocompatible materials such as silica, liposomes, or polymeric micelles provides a physical barrier that prevents leaching of toxic metal ions. For instance, silica-coated CdSe/ZnS QDs demonstrate markedly lower cytotoxicity due to restricted ion release and improved colloidal stability [55-56].

Surface passivation using inert shell materials (e.g., ZnS or ZnSe) enhances photostability and reduces surface defect sites that facilitate degradation. This core–shell architecture not only prevents direct contact between the toxic core and biological milieu but also improves quantum efficiency.

Another effective approach involves biodegradable coatings made from natural polymers like chitosan, gelatin, or dextran. These coatings facilitate gradual degradation and clearance while offering sites for ligand attachment. PEGylation and zwitterionic surface engineering further reduce opsonization and immune recognition, enhancing blood circulation and minimizing accumulation in the RES.

Additionally, green synthesis approaches—employing plant extracts or benign precursors—are gaining traction for producing inherently biocompatible QDs, such as carbon or silicon quantum dots, without the use of hazardous reagents. These methods combine environmental sustainability with safety, aligning with current regulatory trends for biomedical nanomaterials.

Recent case studies have demonstrated significant progress in improving the pharmacokinetic profile and safety of quantum dots. For instance, PEGylated CdSe/ZnS QDs administered intravenously in mice exhibited prolonged circulation half-life and reduced hepatic accumulation compared to non-coated QDs. Similarly, InP/ZnS QDs functionalized with peptides for tumor targeting achieved selective accumulation in tumor tissues with minimal toxicity to healthy organs.

Another study utilized carbon quantum dots conjugated with doxorubicin for breast cancer therapy. The conjugate achieved pH-responsive drug release, enhanced cellular uptake, and real-time imaging capability while showing negligible cytotoxicity in normal cells. These examples illustrate how surface modification and core selection can transform QDs from potentially hazardous materials into safe and effective biomedical tools [57-58].

Further, silicon-based quantum dots have shown promising results in long-term biodistribution studies, exhibiting rapid renal clearance and no detectable tissue damage. Such advancements underscore the feasibility of QDs as clinically viable nanocarriers when engineered with safety and biodegradability in mind.

8. Challenges and Limitations

Despite their transformative potential in pharmacology, diagnostics, and drug delivery, quantum dots (QDs) still face several scientific, technical, and regulatory barriers that restrict their clinical application. While they have proven highly efficient in *in vitro* and *preclinical* studies, the transition to *in vivo* and human use presents multiple unresolved challenges. These range from their long-term toxicity and environmental stability to manufacturing One of the most persistent and serious challenges in the biomedical use of QDs is their long-term toxicity, primarily stemming from the presence of heavy metals such as cadmium (Cd), selenium (Se), and tellurium (Te) in their core structures. Classical QDs like CdSe, CdTe, and CdS exhibit excellent optical properties but pose a significant risk of metal ion leakage, especially under physiological or oxidative stress conditions. This release of Cd^{2+} or other heavy-metal ions can lead to mitochondrial dysfunction, oxidative stress, DNA damage, and apoptosis in mammalian cells.

Even with protective surface coatings like ZnS shells or PEG layers, degradation over time or under high light exposure can compromise the stability of the coating, allowing metal ions to leach into tissues. These ions can bioaccumulate in vital organs such as the liver, spleen, and kidneys, leading to chronic toxicity. Animal studies have shown that cadmium-based QDs may remain in the body for weeks or even months, triggering inflammation, fibrosis, and potential carcinogenic effects.

Although Cd-free alternatives—such as indium phosphide (InP), copper indium sulfide ($CuInS_2$), and carbon quantum dots (CQDs)—offer safer profiles, concerns remain about the incomplete understanding of their long-term biodegradation and clearance. The complex biological milieu can alter QD physicochemical properties, leading to unpredictable biotransformation. Furthermore, the oxidative stress and immune activation induced by certain surface coatings or ligands must also be carefully evaluated for chronic exposure. Therefore, achieving *truly non-toxic and biodegradable QDs* remains a formidable task.

Quantum dots are inherently sensitive nanostructures whose stability in physiological environments directly affects their performance and safety. When exposed to biological fluids rich in salts, proteins, and enzymes, QDs may undergo aggregation, oxidation, or photobleaching, leading to reduced fluorescence intensity and altered pharmacokinetics. This instability can compromise imaging accuracy and drug delivery efficiency.

Protein corona formation—a phenomenon in which plasma proteins adsorb onto the QD surface—further complicates matters. The formation of a protein corona can mask targeting ligands, alter surface charge, and change biodistribution, reducing targeting efficiency. This interaction also increases recognition by the mononuclear phagocyte system (MPS), resulting in rapid clearance from circulation.

Environmental conditions such as pH, ionic strength, and redox potential can also destabilize the QD surface. For example, acidic environments (like in lysosomes or tumor tissues) can degrade QD coatings, releasing toxic ions. Similarly, oxidative conditions can compromise passivating layers, reducing quantum yield and promoting ion leakage [59-60].

Efforts to enhance stability—through robust surface passivation, cross-linked polymer coatings, and inert shell structures—have achieved progress, yet ensuring consistent long-term stability *in vivo* remains elusive. Additionally, maintaining fluorescence performance while ensuring biodegradability presents a delicate engineering trade-off that is still being optimized.

While laboratory-scale synthesis of QDs has been well established, scaling up production without compromising quality, uniformity, or reproducibility remains a significant challenge. The precise optical and biological properties of QDs are highly dependent on particle size, shape, composition, and surface chemistry, all of which are extremely sensitive to minor variations in reaction conditions. Factors like temperature, precursor concentration, and reaction time must be tightly controlled to achieve uniform particle populations.

Batch-to-batch variability is a major issue, as even slight inconsistencies can result in variations in fluorescence emission, quantum yield, or biocompatibility. This lack of reproducibility undermines both scientific reproducibility and regulatory approval for medical applications. Furthermore, large-scale synthesis often requires toxic organic solvents, high temperatures, or hazardous precursors, which not only raise safety and environmental concerns but also limit cost-effectiveness and scalability.

Although green synthesis techniques and microfluidic-based manufacturing approaches have emerged as promising alternatives, they are still in early development stages and lack the precision and consistency required for industrial-scale biomedical use. Achieving scalable, standardized, and *GMP-compliant* (Good Manufacturing Practice) production remains one of the most critical bottlenecks for QD commercialization in healthcare [61].

Beyond technical and toxicological issues, regulatory and ethical barriers pose some of the most formidable challenges to the clinical translation of QDs. Because QDs straddle the line between drugs, devices, and biologics, their classification under existing regulatory frameworks is often ambiguous. Agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) require comprehensive safety data on pharmacokinetics, toxicity, and long-term biocompatibility before approving new nanomaterials for human use. However, the lack of standardized testing protocols and long-term in vivo data hinders regulatory assessment.

Additionally, ethical concerns arise from the potential environmental impact of QD production and disposal. The release of heavy metals or persistent nanomaterials into ecosystems can lead to bioaccumulation in aquatic life and soil contamination, raising public health and ecological concerns. Therefore, developing eco-friendly synthesis methods and biodegradable formulations is not only a scientific necessity but also a regulatory requirement for future approval.

The ethical use of nanomaterials in humans also raises questions about patient consent, long-term monitoring, and unforeseen biological effects. Since nanomaterials behave differently from traditional drugs, their unpredictable interactions with biological systems necessitate cautious, transparent communication with patients and regulatory authorities. Moreover, intellectual property disputes and lack of harmonized global regulations further complicate commercialization and cross-border research collaborations [62-63].

To move forward, establishing clear regulatory guidelines and safety assessment frameworks tailored for nanomedicine is critical. Collaborative efforts between scientists, regulators, and ethicists will be required to build trust, ensure safety, and accelerate the responsible clinical integration of QD-based technologies.

9. Future Perspectives

The future of quantum dots (QDs) in pharmacology is heading toward a new era of innovation that blends material science, artificial intelligence, and precision medicine. As research continues to refine their biocompatibility, stability, and functionality, QDs are poised to play a defining role in next-generation drug delivery, bioimaging, and theranostic platforms. The coming years will likely witness a transition from conventional cadmium-based QDs to eco-friendly, metal-free nanomaterials, the rise of AI-assisted imaging systems, and the emergence of hybrid nanostructures that combine therapeutic and diagnostic capabilities in one intelligent platform.

One of the most promising future directions involves designing eco-friendly, metal-free quantum dots that retain the optical brilliance of traditional semiconductor QDs while eliminating toxicity concerns. Carbon quantum dots (CQDs), silicon quantum dots (SiQDs), graphene quantum dots (GQDs), and perovskite quantum dots (PQDs) are emerging as next-generation alternatives to cadmium- and lead-based systems.

Carbon quantum dots (CQDs), derived from organic precursors like citric acid, carbohydrates, or even biomass waste, exhibit excellent water solubility, biocompatibility, and low cytotoxicity. They offer tunable fluorescence across visible and near-infrared (NIR) spectra, making them ideal for bioimaging, drug tracking, and photothermal therapy. Moreover, their synthesis via green chemistry routes—such as hydrothermal carbonization or microwave-assisted processing—aligns with the global shift toward sustainable nanotechnology [64-65].

Silicon quantum dots (SiQDs), another notable candidate, possess strong photoluminescence, biodegradability, and minimal immunogenicity. They are particularly attractive for in vivo applications because silicon degrades into orthosilicic acid, a naturally excretable compound. Similarly, graphene QDs (GQDs) offer excellent electron mobility and surface functionalization potential, enabling dual applications in drug delivery and biosensing.

Lead-free perovskite QDs, especially those based on tin (Sn) or bismuth (Bi), are also gaining attention for their tunable emission and high quantum yields. However, their stability in aqueous environments remains a challenge that ongoing research aims to address through encapsulation in biopolymers or lipid matrices. Collectively, the move toward biodegradable, metal-free QDs represents a paradigm shift toward safer, more sustainable nanomedicine.

As biomedical data grows exponentially, the integration of artificial intelligence (AI) with QD-based imaging and therapy is expected to redefine clinical diagnostics and personalized medicine. AI algorithms, particularly in deep learning and computer vision, can analyze complex bioimaging datasets generated from QD-based systems to identify subtle physiological or pathological changes with unprecedented accuracy.

By coupling QDs' multiplexed imaging capabilities—where different QDs emit at distinct wavelengths—with AI-powered pattern recognition, clinicians can detect molecular biomarkers, tumor margins, or drug response profiles in real time. This AI-QD synergy will allow for more precise disease characterization, earlier diagnosis, and dynamic monitoring of treatment responses [66-67].

In pharmacology, AI can also assist in predicting the pharmacokinetics and biodistribution of QDs across tissues, optimizing dose selection and minimizing toxicity risks. Furthermore, integrating QDs into wearable or implantable biosensing platforms combined with AI analytics could enable continuous, personalized health monitoring—ushering in the age of smart, self-regulating nanomedicine systems [68].

10. Conclusion

Quantum dots (QDs) have emerged as one of the most dynamic and versatile tools in modern pharmacology, offering a unique bridge between diagnostics and therapeutics through their dual functionality in imaging and drug delivery. Their exceptional optical and electronic properties, such as size-tunable fluorescence, high quantum yield, and remarkable photostability, have established them as superior alternatives to traditional organic dyes and fluorescent probes. Beyond mere imaging, QDs now occupy a central position in theranostics, enabling simultaneous disease diagnosis, targeted therapy, and real-time monitoring of treatment efficacy—all within a single nanosystem.

From a pharmacological standpoint, QDs provide a powerful means to visualize molecular and cellular processes, track drug distribution, and assess biodistribution in vivo with unprecedented clarity. Their tunable surface chemistry allows conjugation with a wide range

of biomolecules—drugs, peptides, antibodies, or nucleic acids—offering targeted drug delivery and enhanced therapeutic specificity. Moreover, their ability to be engineered for stimuli-responsive drug release (via pH, enzyme, or light activation) adds another layer of control, making them ideal candidates for precision therapy, particularly in oncology, neurology, and infectious disease management.

However, the clinical translation of QDs remains hindered by safety concerns, primarily due to the presence of toxic heavy metals like cadmium and lead in many traditional semiconductor QDs. Issues related to long-term accumulation, oxidative stress, and potential genotoxicity have underscored the urgent need for biocompatible and degradable alternatives. Encouragingly, recent advances in carbon-, silicon-, and graphene-based QDs, as well as lead-free perovskite nanomaterials, are paving the way for safer and more sustainable nanoplatforms. These innovations not only mitigate toxicity risks but also preserve the optical brilliance and functional versatility that define QDs' success in biomedical applications.

The integration of artificial intelligence (AI) and data-driven analytics into QD-based systems represents another frontier of pharmacological advancement. AI-assisted imaging interpretation, machine learning-guided drug targeting, and predictive modeling of QD pharmacokinetics hold the promise of revolutionizing how clinicians diagnose, treat, and monitor diseases. As QDs continue to evolve from experimental tools to clinically applicable nanodevices, their role in personalized medicine will become increasingly pronounced—offering patient-specific solutions that adapt dynamically to therapeutic needs.

In the broader context of next-generation nanomedicine, quantum dots symbolize the convergence of materials science, molecular biology, and digital technology. Their potential to merge diagnostics and therapeutics into a unified, intelligent platform epitomizes the future of healthcare—one that is precise, responsive, and minimally invasive. With continued interdisciplinary collaboration, regulatory clarity, and innovation in eco-friendly synthesis, QDs could transition from research laboratories to clinical practice, ushering in a new paradigm of smart, safe, and targeted pharmacological interventions.

In conclusion, while challenges remain in terms of safety, scalability, and regulatory validation, the trajectory of quantum dot research points decisively toward clinical translatability. The development of biocompatible, metal-free, and multifunctional QDs will be crucial to unlocking their full therapeutic and diagnostic potential. Ultimately, the fusion of quantum nanotechnology with pharmacology is set to redefine precision medicine—transforming disease detection and treatment into a single, seamless, and highly efficient process that marks the next evolutionary leap in biomedical innovation.

References

1.Mohsenpour, S., & Khosravanian, A. (2018). Influence of additives on the morphology of PVDF membranes based on phase diagram: Thermodynamic and experimental study. *Journal of Applied Polymer Science, 135*, 46225.

2.Khosravanian, A., Dehghani, M., Pazirofteh, M., Asghari, M., Mohammadi, A. H., & Shahsavari, D. (2018). Grand canonical Monte Carlo and molecular dynamics simulations of the structural properties, diffusion and adsorption of hydrogen molecules through poly(benzimidazoles)/nanoparticle oxides composites. *International Journal of Hydrogen Energy, 43*, 2803–2816.

3.Adir, O., Poley, M., Chen, G., Froim, S., Krinsky, N., Shklover, J., Shainsky-Roitman, J., Lammers, T., & Schroeder, A. (2020). Integrating artificial intelligence and nanotechnology for precision cancer medicine. *Advanced Materials, 32*, 1901989.

4.Abbasi-Moayed, S., Hormozi-Nezhad, M. R., & Maaza, M. (2019). A multichannel single-well sensor array for rapid and visual discrimination of catecholamine neurotransmitters. *Sensors and Actuators B: Chemical, 296*, 126691.

5. Dal Poggetto, G., Troise, S. S., Conte, C., Marchetti, R., Moret, F., Iadonisi, A., Silipo, A., Lanzetta, R., Malinconico, M., & Quaglia, F. (2020). Nanoparticles decorated with folate based on a site-selective αCD-rotaxanated PEG-b-PCL copolymer for targeted cancer therapy. *Polymer Chemistry*.

6. Liu, H., Li, C., Qian, Y., Hu, L., Fang, J., Tong, W., Nie, R., Chen, Q., & Wang, H. (2020). Magnetic-induced graphene quantum dots for imaging-guided photothermal therapy in the second near-infrared window. *Biomaterials, 232*, 119700.

7. Akbarzadeh, M., Babaei, M., Abnous, K., Taghdisi, S. M., Peivandi, M. T., Ramezani, M., & Alibolandi, M. (2019). Hybrid silica-coated Gd-Zn-Cu-In-S/ZnS bimodal quantum dots as an epithelial cell adhesion molecule targeted drug delivery and imaging system. *International Journal of Pharmaceutics, 570*, 118645.

8. Sun, W., & Wu, F. G. (2018). Two-dimensional materials for antimicrobial applications: Graphene materials and beyond. *Chemistry – An Asian Journal, 13*, 3378–3410.

9. Samadi, N., & Narimani, S. (2019). Simple and sensitive photoluminescent detection of meropenem using Cit-capped CdS quantum dots as a fluorescence probe. *Analytical and Bioanalytical Chemistry Research, 6*, 47–57.

10. Tian, J., Chen, J., Liu, J., Tian, Q., & Chen, P. (2018). Graphene quantum dot engineered nickel-cobalt phosphide as highly efficient bifunctional catalyst for overall water splitting. *Nano Energy, 48*, 284–291.

11. Zhao, X., Gao, W., Zhang, H., Qiu, X., & Luo, Y. (2020). Graphene quantum dots in biomedical applications: Recent advances and future challenges. In *Handbook of Nanomaterials in Analytical Chemistry* (pp. 493–505). Elsevier.

12. Mansuriya, B. D., & Altintas, Z. (2020). Applications of graphene quantum dots in biomedical sensors. *Sensors, 20*, 1072.

13. Bayoumy, A. M., Refaat, A., Yahia, I. S., Zahran, H. Y., Elhaes, H., Ibrahim, M. A., & Shkir, M. (2020). Functionalization of graphene quantum dots with chitosan biopolymer for biophysical applications. *Optical and Quantum Electronics, 52*, 16.

14. Karimzadeh, A., Hasanzadeh, M., Shadjou, N., & de la Guardia, M. (2018). Optical biosensing using nitrogen-doped graphene quantum dots: Recent advances and future challenges. *TrAC Trends in Analytical Chemistry, 108*, 110–121.

15.Şenel, B., Demir, N., Büyükköroğlu, G., & Yıldız, M. (2019). Graphene quantum dots: Synthesis, characterization, cell viability, genotoxicity for biomedical applications. *Saudi Pharmaceutical Journal, 27*, 846–858.

16. Ananthanarayanan, A., Wang, X., Routh, P., Sana, B., Lim, S., Kim, D. H., Lim, K. H., Li, J., & Chen, P. (2014). Facile synthesis of graphene quantum dots from 3D graphene and their application for Fe^{3+} sensing. *Advanced Functional Materials, 24*, 3021–3026.

17. Khan, Z. G., & Patil, P. O. (2020). A comprehensive review on carbon dots and graphene quantum dots based fluorescent sensor for biothiols. *Microchemical Journal*, 105011.

18. Shehab, M., Ebrahim, S., & Soliman, M. (2017). Graphene quantum dots prepared from glucose as optical sensor for glucose. *Journal of Luminescence, 184*, 110–116.

19. Benítez-Martínez, S., & Valcárcel, M. (2015). Graphene quantum dots in analytical science. *TrAC Trends in Analytical Chemistry, 72*, 93–113.

20. Chen, W., Li, D., Tian, L., Xiang, W., Wang, T., Hu, W., Hu, Y., Chen, S., Chen, J., & Dai, Z. (2018). Synthesis of graphene quantum dots from natural polymer starch for cell imaging. *Green Chemistry, 20*, 4438–4442.

21. Wang, L., Zhu, S.-J., Wang, H.-Y., Qu, S.-N., Zhang, Y.-L., Zhang, J.-H., Chen, Q.-D., Xu, H.-L., Han, W., & Yang, B. (2014). Common origin of green luminescence in carbon nanodots and graphene quantum dots. *ACS Nano, 8*, 2541–2547.

22. Yan, Y., Gong, J., Chen, J., Zeng, Z., Huang, W., Pu, K., Liu, J., & Chen, P. (2019). Recent advances on graphene quantum dots: From chemistry and physics to applications. *Advanced Materials, 31*, 1808283.

23. Hai, X., Feng, J., Chen, X., & Wang, J. (2018). Tuning the optical properties of graphene quantum dots for biosensing and bioimaging. *Journal of Materials Chemistry B, 6*, 3219–3234.

24. Zheng, P., & Wu, N. (2017). Fluorescence and sensing applications of graphene oxide and graphene quantum dots: A review. *Chemistry – An Asian Journal, 12*, 2343–2353.

25. Yan, C., Hu, X., Guan, P., Hou, T., Chen, P., Wan, D., Zhang, X., Wang, J., & Wang, C. (2020). Highly biocompatible graphene quantum dots: Green synthesis, toxicity comparison, and fluorescence imaging. *Journal of Materials Science, 55*, 1198–1215.

26. Salehnia, F., Faridbod, F., Dezfuli, A. S., Ganjali, M. R., & Norouzi, P. (2017). Cerium(III) ion sensing based on graphene quantum dots fluorescent turn-off. *Journal of Fluorescence, 27*, 331–338.

27. Li, K., Zhao, X., Wei, G., & Su, Z. (2018). Recent advances in cancer bioimaging with graphene quantum dots. *Current Medicinal Chemistry, 25*, 2876–2893.

28. Iannazzo, D., Ziccarelli, I., & Pistone, A. (2017). Graphene quantum dots: Multifunctional nanoplatforms for anticancer therapy. *Journal of Materials Chemistry B, 5*, 6471–6489.

29. Naik, J. P., Sutradhar, P., & Saha, M. (2017). Molecular scale rapid synthesis of graphene quantum dots (GQDs). *Journal of Nanostructure in Chemistry, 7*, 85–89.

30. Kalluri, A., Debnath, D., Dharmadhikari, B., & Patra, P. (2018). Graphene quantum dots: Synthesis and applications. In *Methods in Enzymology* (pp. 335–354). Elsevier.

31. Hormozi-Nezhad, M. R., Moslehipour, A., & Bigdeli, A. (2017). Simple and rapid detection of L-dopa based on in situ formation of polylevodopa nanoparticles. *Sensors and Actuators B: Chemical, 243*, 715–720.

32. Moslehipour, A. (2020). Recent advances in fluorescence detection of catecholamines. *Journal of Chemical Reviews*, 130–147.

33. Moslehipour, A., Bigdeli, A., Ghasemi, F., & Hormozi-Nezhad, M. R. (2019). Design of a ratiometric fluorescence nanoprobe to detect plasma levels of levodopa. *Microchemical Journal, 148*, 591–596.

34. Kim, T.-H., Lee, D., & Choi, J.-W. (2017). Live cell biosensing platforms using graphene-based hybrid nanomaterials. *Biosensors and Bioelectronics, 94*, 485–499.

35. Morales-Narváez, E., & Merkoçi, A. (2019). Graphene oxide as an optical biosensing platform: A progress report. *Advanced Materials, 31*, 1805043.

36. Tian, P., Tang, L., Teng, K., & Lau, S. (2018). Graphene quantum dots from chemistry to applications. *Materials Today Chemistry, 10*, 221–258.

37. Walther, B. K., Dinu, C. Z., Guldi, D. M., Sergeyev, V. G., Creager, S. E., Cooke, J. P., & Guiseppi-Elie, A. (2020). Nanobiosensing with graphene and carbon quantum dots: Recent advances. *Materials Today*.

38. Henna, T., & Pramod, K. (2020). Graphene quantum dots redefine nanobiomedicine. *Materials Science and Engineering: C, 110*, 110651.

39. Bahadır, E. B., & Sezgintürk, M. K. (2016). Applications of graphene in electrochemical sensing and biosensing. *Trends in Analytical Chemistry, 76*, 1–14.

40. Mastar, A. A., Abdullah, J., Yusof, N. A., & Fen, Y. W. (2019). An optical sensor based on graphene quantum dots for hydrogen peroxide detection. *Malaysian Journal of Analytical Sciences, 23*, 572–579.

41. Cai, N., Tan, L., Li, Y., Xia, T., Hu, T., & Su, X. (2017). Biosensing platform for detection of uric acid based on graphene quantum dots and G-quadruplex/hemin DNAzyme. *Analytica Chimica Acta, 965*, 96–102.

42. Cui, F., Ji, J., Sun, J., Wang, J., Wang, H., Zhang, Y., Ding, H., Lu, Y., Xu, D., & Sun, X. (2019). A magnetic fluorescent biosensor based on graphene quantum dots for rapid detection of circulating tumor cells. *Analytical and Bioanalytical Chemistry, 411*, 985–995.

43. Hatamluyi, B., & Es'haghi, Z. (2018). Electrochemical biosensing based on MIP reinforced by ZnO–graphene quantum dots for 6-mercaptopurine detection. *Electrochimica Acta, 283*, 1170–1177.

44. Yang, S., Chu, M., Du, J., Li, Y., Gai, T., Tan, X., Xia, B., & Wang, S. (2020). Graphene quantum dot electrochemiluminescence enhanced by biogenerated H_2O_2 for direct biosensing. *Royal Society Open Science, 7*, 191404.

45. Jie, G., Zhou, Q., & Jie, G. (2019). Graphene quantum dots–based electrochemiluminescence detection of DNA using multiple cycling amplification. *Talanta, 194*, 658–663.

46. Tian, C., Wang, L., Luan, F., & Zhuang, X. (2019). Electrochemiluminescence sensor for prostate antigen detection using GQD-filled TiO_2 nanotube arrays. *Talanta, 191*, 103–108.

47. Verma, V. S., Sakure, K., & Badwaik, H. R. (2017). Xanthan Gum a Versatile Biopolymer: Current Status and Future Prospectus in Hydro Gel Drug Delivery. *Current Chemical Biology*, *11*(1), 10–20. https://doi.org/10.2174/2212796810666161110152815.

48. He, L., Yang, L., Zhu, H., Dong, W., Ding, Y., & Zhu, J.-J. (2017). Biosensing platform using UCNPs and GQDs for Ag^+ detection. *Methods and Applications in Fluorescence, 5*, 024010.

49. Li, L., Liu, D., Wang, K., Mao, H., & You, T. (2017). Quantitative nitrite detection using N-doped GQDs and N-doped carbon nanofibers. *Sensors and Actuators B: Chemical, 252*, 17–23.

50. Beheshti-Marnani, A., Hatefi-Mehrjardi, A., & Es'haghi, Z. (2019). Detection of AFB1 using aptamer/reduced graphene oxide nano-bio interaction. *Colloids and Surfaces B: Biointerfaces, 175*, 98–105.

51. Ren, X., Ma, H., Zhang, T., Zhang, Y., Yan, T., Du, B., & Wei, Q. (2017). Sulfur-doped graphene immunosensing platform for multiplex cancer biomarker analysis. *ACS Applied Materials & Interfaces, 9*, 37637–37644.

52. Verma, V. S. (2025). Development of Multi-Target Directed Ligands for Neurodegenerative Disorders: A Medicinal Chemistry Approach. *Interconnected Journal of Chemistry and Pharmaceutical Sciences (IJCPS)*, *01*, 49–65. https://ijcps.nknpub.com/1/article/view/9

53. Sharma, D., Kanchi, S., Sabela, M. I., & Bisetty, K. (2016). Biosensing with graphene oxide: Present and future. *Arabian Journal of Chemistry, 9*, 238–261.

54. Thangamuthu, M., Hsieh, K. Y., Kumar, P. V., & Chen, G.-Y. (2019). Graphene/graphene oxide nanocomposite platforms for electrochemical biosensing. *International Journal of Molecular Sciences, 20*, 2975.

55. Hassanvand, Z., & Jalali, F. (2018). Electrocatalytic glutathione detection using MHCFs of copper and cobalt on graphene oxide nanosheets. *Analytical and Bioanalytical Chemistry Research, 5*, 115–129.

56. Tajik, S., & Beitollahi, H. (2019). Chlorpromazine voltammetric sensor based on graphene oxide modified electrode. *Analytical and Bioanalytical Chemistry Research, 6*, 171–182.

57. Cheeveewattanagul, N., Morales-Narváez, E., Hassan, A. R. H., Bergua, J. F., Surareungchai, W., Somasundrum, M., & Merkoçi, A. (2017). Graphene oxide–decorated nanopaper immunosensing platform. *Advanced Functional Materials, 27*, 1702741.

58. Ge, S., Lan, F., Liang, L., Ren, N., Li, L., Liu, H., Yan, M., & Yu, J. (2017). Ultrasensitive PEC biosensing of cell surface N-glycans using nanogold-mesoporous silica amplified by GQDs. *ACS Applied Materials & Interfaces, 9*, 6670–6678.

59. Li, N., Li, R., Li, Z., Yang, Y., Wang, G., & Gu, Z. (2019). Pentaethylenehexamine- and histidine-functionalized GQDs for microRNA detection. *Sensors and Actuators B: Chemical, 283*, 666–676.

60. Conte, C., Moret, F., Esposito, D., Dal Poggetto, G., Avitabile, C., Ungaro, F., Romanelli, A., Laurienzo, P., Reddi, E., & Quaglia, F. (2019). Biodegradable nanoparticles exposing anti-FLT1 peptide to complement docetaxel therapy. *Materials Science and Engineering: C, 102*, 876–886.

61. Sinha, S., Tripathi, A. K., Pandey, A., Naik, P., Pandey, A., & Verma, V. S. (2024). Self-assembled PEGylated micelles for precise and targeted drug delivery: Current challenges and future directions. *Biocatalysis and Agricultural Biotechnology*, *60*. https://doi.org/10.1016/J.BCAB.2024.103296

62. d'Angelo, I., Costabile, G., Durantie, E., Brocca, P., Rondelli, V., Russo, A., Russo, G., Miro, A., Quaglia, F., & Petri-Fink, A. (2018). Hybrid lipid/polymer nanoparticles for pulmonary siRNA delivery. *Journal of Aerosol Medicine and Pulmonary Drug Delivery, 31*, 170–181.

63. Pourbadiei, B., Pyadar, R., & Mansouri, F. (2017). pH-sensitive nanoscale polymers for DOX delivery in cancer. *Journal of Nanomedicine Research, 5*, 1–6.

64. Faraji, H., Nedaeinia, R., Nourmohammadi, E., Malaekeh-Nikouei, B., Sadeghnia, H. R., Ziapour, S. P., Sarkarizi, H. K., & Oskuee, R. K. (2018). Novel solid nanostructures in drug delivery. *Journal of Nano Research*.

65. Goyal, A. K., Rath, G., Faujdar, C., & Malik, B. (2019). pH-responsive nano drug delivery systems. In *Applications of Targeted Nano Drugs and Delivery Systems* (pp. 15–33). Elsevier.

66. Patra, J. K., Das, G., Fraceto, L. F., Campos, E. V. R., Rodriguez-Torres, M. P., Acosta-Torres, L. S., Diaz-Torres, L. A., Grillo, R., Swamy, M. K., & Sharma, S. (2018). Nano-based drug delivery systems: Developments and future prospects. *Journal of Nanobiotechnology, 16*, 71.

67. Probst, C. E., Zrazhevskiy, P., Bagalkot, V., & Gao, X. (2013). Quantum dots as nanoparticle drug delivery vehicles. *Advanced Drug Delivery Reviews, 65*, 703–718.

68. Tashkhourian, J., Akhond, M., Hooshmand, S., Khosousi, T., & Hemmateenejad, B. (2014). Glucose determination using CdTe/TGA QDs and image analysis. *Analytical and Bioanalytical Chemistry Research, 1*, 117–127.